ATE541833T1 - Stickstoff-enthaltende verbindungen mit kinasehemmender wirkung sowie diese enthaltende medikamente - Google Patents

Stickstoff-enthaltende verbindungen mit kinasehemmender wirkung sowie diese enthaltende medikamente

Info

Publication number
ATE541833T1
ATE541833T1 AT01902730T AT01902730T ATE541833T1 AT E541833 T1 ATE541833 T1 AT E541833T1 AT 01902730 T AT01902730 T AT 01902730T AT 01902730 T AT01902730 T AT 01902730T AT E541833 T1 ATE541833 T1 AT E541833T1
Authority
AT
Austria
Prior art keywords
group
kinase
nitrogen
inhibiting effects
medications
Prior art date
Application number
AT01902730T
Other languages
English (en)
Inventor
Atsuya Takami
Hiroshi Iijima
Masayuki Iwakubo
Yuji Okada
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of ATE541833T1 publication Critical patent/ATE541833T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT01902730T 2000-02-01 2001-02-01 Stickstoff-enthaltende verbindungen mit kinasehemmender wirkung sowie diese enthaltende medikamente ATE541833T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000024292 2000-02-01
PCT/JP2001/000721 WO2001056988A1 (en) 2000-02-01 2001-02-01 Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same

Publications (1)

Publication Number Publication Date
ATE541833T1 true ATE541833T1 (de) 2012-02-15

Family

ID=18550309

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01902730T ATE541833T1 (de) 2000-02-01 2001-02-01 Stickstoff-enthaltende verbindungen mit kinasehemmender wirkung sowie diese enthaltende medikamente

Country Status (6)

Country Link
US (1) US7217722B2 (de)
EP (1) EP1256574B1 (de)
AT (1) ATE541833T1 (de)
AU (1) AU2001230564A1 (de)
ES (1) ES2377556T3 (de)
WO (1) WO2001056988A1 (de)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109208B2 (en) 2001-04-11 2006-09-19 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
WO2002100833A1 (en) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
JP5042419B2 (ja) * 2001-08-15 2012-10-03 旭化成ファーマ株式会社 骨形成促進剤および骨形成促進組成物
BR0212841A (pt) * 2001-09-26 2004-08-03 Pharmacia Italia Spa Derivado ativo de aminoindazole como inibidores de cinase, processo para sua preparação e composições farmacêuticas que os contém
EP1447400B1 (de) * 2001-10-25 2008-09-17 Asahi Kasei Pharma Corporation Bicyclische verbindung
JP2003192587A (ja) * 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
US7094789B2 (en) 2002-07-22 2006-08-22 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivatives
EP1541559A4 (de) * 2002-07-22 2007-08-22 Asahi Kasei Pharma Corp 5-substituiertes isochinolinderivat
AU2003257588A1 (en) 2002-08-29 2004-03-19 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
AU2003264427A1 (en) * 2002-09-12 2004-04-30 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
AU2003286711A1 (en) * 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7160894B2 (en) 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
US7015233B2 (en) 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US7375126B2 (en) 2003-06-12 2008-05-20 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
EP1699777B1 (de) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidylpeptidase-hemmer
GB0322016D0 (en) * 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
JP2007506787A (ja) 2003-09-23 2007-03-22 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとしてのピラゾロピロール誘導体
WO2005039564A1 (en) * 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
EP1679308B1 (de) * 2003-10-15 2013-07-24 Ube Industries, Ltd. Neues indazolderivat
DE10357510A1 (de) * 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroarylsubstituierte Benzole
FR2864084B1 (fr) * 2003-12-17 2006-02-10 Aventis Pharma Sa Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments
WO2005082858A2 (en) * 2004-02-26 2005-09-09 Merck Patent Gmbh Isoquinoline derivatives
UA85871C2 (uk) 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Інгібітори дипептидилпептидази
EP1831225A2 (de) * 2004-11-19 2007-09-12 The Regents of the University of California Entzündungshemmende pyrazolopyrimidine
US20060247266A1 (en) * 2004-11-26 2006-11-02 Asahi Kasei Pharma Corporation Nitrogen-containing tricyclic compounds
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
KR101396731B1 (ko) 2005-03-31 2014-05-19 산텐 세이야꾸 가부시키가이샤 프로스타글란딘 Ｆ２ａ 유도체를 유효 성분으로서 함유하는망막신경세포 보호제
CN101160128B (zh) * 2005-04-13 2010-08-18 宇部兴产株式会社 含有吲唑衍生物作为有效成分的视网膜神经细胞保护剂
CN101198354B (zh) 2005-06-21 2012-01-11 兴和株式会社 青光眼的预防或治疗剂
CN101213187B (zh) 2005-06-28 2012-06-06 塞诺菲-安万特股份有限公司 作为rho-激酶抑制剂的异喹啉衍生物
KR101333990B1 (ko) 2005-07-12 2013-11-27 코와 가부시키가이샤 녹내장을 예방 또는 치료하는 약제
RS52241B (sr) * 2005-07-26 2012-10-31 Sanofi Derivati cikloheksilamin izohinolona kao inhibitori rho-kinaze
CA2615577C (en) * 2005-07-26 2014-09-09 Sanofi-Aventis Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
CA2621181C (en) * 2005-08-30 2011-04-19 Asahi Kasei Pharma Corporation 5-isoquinolinesulfonamide compounds
US8211919B2 (en) 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
MY147393A (en) 2005-09-14 2012-11-30 Takeda Pharmaceutical Administration of dipeptidyl peptidase inhibitors
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
KR20080103584A (ko) * 2006-03-30 2008-11-27 아사히 가세이 파마 가부시키가이샤 치환 이환식 환상 유도체 및 그 용도
WO2007114926A2 (en) 2006-04-04 2007-10-11 The Regents Of The University Of California Kinase antagonists
RU2008152065A (ru) 2006-06-08 2010-07-20 Убе Индастриз, Лтд (Jp) Новое производное имидазола со спироциклической структурой в боковой цепи
EP1891958A1 (de) * 2006-08-03 2008-02-27 Universite Pierre Et Marie Curie (Paris Vi) Rho/Rock/PI3/Akt Kinase Inhibitoren zur Behandlung von Krankheiten assoziiert mit Protozoen Parasiten.
WO2008019967A2 (en) 2006-08-15 2008-02-21 F. Hoffmann-La Roche Ag Phenyl, pyridine and quinoline derivatives
CA2661898A1 (en) 2006-08-25 2008-02-28 Abbott Laboratories Indazole derivatives that inhibit trpv1 and uses thereof
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8071779B2 (en) * 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
BRPI0722095A2 (pt) * 2006-12-20 2014-04-01 Astrazeneca Ab Derivados de amina e seu uso em doenças mediadas por beta-2-adrenor-receptor
CA2672196A1 (en) 2006-12-20 2008-07-03 Abbott Laboratories Antagonists of the trpv1 receptor and uses thereof
BRPI0720986A2 (pt) * 2006-12-27 2014-03-11 Sanofi Aventis Derivados de isoquinolina e isoquinolinona substituídos
PT2125744E (pt) * 2006-12-27 2011-07-01 Sanofi Aventis Derivados de isoquinolona e isoquinolinona substituídos com cicloalquilamina
NZ577980A (en) * 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
MY148902A (en) * 2006-12-27 2013-06-14 Sanofi Aventis Substituted isoquinolines and their use as rho-kinase inhibitors
JP5421783B2 (ja) 2006-12-27 2014-02-19 サノフイ Ｒｈｏキナーゼ阻害剤としての置換イソキノロン及びイソキノリノン誘導体
RU2468011C2 (ru) * 2006-12-27 2012-11-27 Санофи-Авентис Замещенные циклоалкиламином производные изохинолина и изохинолинона
MX2009005964A (es) * 2006-12-27 2009-06-15 Sanofi Aventis Derivados de isoquinolina sustituidos con cicloalquilamina.
CL2007003874A1 (es) * 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
US8415372B2 (en) * 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound
AU2008220104B2 (en) 2007-02-28 2012-09-27 Asahi Kasei Pharma Corporation Sulfonamide derivative
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
ES2396795T3 (es) * 2007-07-02 2013-02-27 Asahi Kasei Pharma Corporation Compuesto de sulfonamida y cirstal del mismo
DK2178870T3 (en) * 2007-08-17 2018-10-22 Lg Chemical Ltd INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE
GB2467670B (en) * 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007419A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8993580B2 (en) * 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (de) 2008-03-14 2018-06-27 Intellikine, LLC Kinasehemmer und verwendungsverfahren
EP2489660A1 (de) 2008-03-20 2012-08-22 Abbott Laboratories Verfahren zum Herstellen von Mitteln für das zentrale Nervensystem, die TRPV1-Antagonisten sind
CN104710365A (zh) 2008-04-28 2015-06-17 旭化成制药株式会社 苯丙酸衍生物及其用途
JP2011524912A (ja) * 2008-06-18 2011-09-08 インスパイアー ファーマシューティカルズ，インコーポレイティド Ｒｈｏキナーゼ阻害化合物の眼科用製剤
MY153615A (en) * 2008-06-24 2015-02-27 Sanofi Aventis 6-substituted isoquinolines and isoquinolinones
MY153756A (en) * 2008-06-24 2015-03-13 Sanofi Aventis Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors
CA2728137C (en) * 2008-06-24 2016-10-18 Sanofi-Aventis Substituted isoquinolines and isoquinolinones as rho kinase inhibitors
US8410147B2 (en) * 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
US20100008968A1 (en) * 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
WO2009158587A1 (en) * 2008-06-26 2009-12-30 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
US8207195B2 (en) * 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
US20090325959A1 (en) * 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
US20090325960A1 (en) * 2008-06-26 2009-12-31 Fulcher Emilee H Method for treating inflammatory diseases using rho kinase inhibitor compounds
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
CA2737349A1 (en) * 2008-10-09 2010-04-09 Asahi Kasei Pharma Corporation Indazole derivatives
CA2740772A1 (en) 2008-10-09 2010-04-15 Asahi Kasei Pharma Corporation Indazole compounds
EP2358720B1 (de) 2008-10-16 2016-03-02 The Regents of The University of California Heteroarylkinasehemmer mit kondensierten ringen
EP2179984A1 (de) 2008-10-27 2010-04-28 Congenia S.r.l. Acrylamid-Verbindungen als Inhibitoren der mitochondriale Permeabilitäts-Transition
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US20100222404A1 (en) * 2008-11-04 2010-09-02 Asahi Kasei Pharma Corporation Indazole derivative dihydrochloride
US20100204210A1 (en) * 2008-12-04 2010-08-12 Scott Sorensen Method for treating pulmonary diseases using rho kinase inhibitor compounds
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
WO2011062765A2 (en) * 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
US8476295B2 (en) * 2009-12-14 2013-07-02 Inspire Bridged bicyclic RHO kinase inhibitor compounds, composition and use
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
EP2597953A4 (de) * 2010-07-27 2013-12-25 Inspire Pharmaceuticals Inc Verfahren zur behandlung von augenkrankheiten unter verwendung von kinasehemmerverbindungen in prodrug-formen
WO2012054367A1 (en) 2010-10-19 2012-04-26 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
EP2638149B1 (de) 2010-11-12 2019-05-15 Georgetown University Immortalisierung von epithelzellen und verwendungsverfahren dafür
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
GB201107223D0 (en) 2011-04-29 2011-06-15 Amakem Nv Novel rock inhibitors
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
EP2628482A1 (de) 2012-02-17 2013-08-21 Academisch Medisch Centrum Rho Kinase Inhibitoren in der Verwendung zur Behandlung von Neuroblastoma
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
IN2015DN04311A (de) 2012-10-31 2015-10-16 Amakem Nv
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
CN107075469A (zh) 2014-06-27 2017-08-18 加利福尼亚大学董事会 培养的哺乳动物角膜缘干细胞、其产生方法和其用途
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
WO2016161192A1 (en) 2015-04-03 2016-10-06 Propagenix Inc. Ex vivo proliferation of epithelial cells
WO2017044454A1 (en) 2015-09-11 2017-03-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
CN105130964A (zh) * 2015-09-28 2015-12-09 侯方杰 一种可用于制备治疗心血管疾病药物的化合物及其制备方法、用途
CN105085492A (zh) * 2015-09-29 2015-11-25 青岛友诚高新技术有限公司 一种可用于制备治疗冠状动脉粥样硬化药物的化合物及其制备方法、用途
CN105130965A (zh) * 2015-10-08 2015-12-09 侯方杰 一种可用于制备治疗心血管疾病药物的化合物及其制备方法、用途
US12048761B2 (en) 2015-10-13 2024-07-30 Inserm (Institut National De La Santé Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
EP4088719A1 (de) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur behandlung von kapillarer nichtperfusion der netzhaut
CN105461700A (zh) * 2015-12-02 2016-04-06 青岛市中心医院 一种可用于制备抗乳腺癌药物的化合物及其制备方法、用途
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
EP3504204A4 (de) * 2016-08-26 2020-05-27 Lycera Corporation Indazolyl-l,2,4-thiadiazolamine und zugehörige verbindungen zur hemmung der rho-assoziierten proteinkinase und zur behandlung von krankheiten
US11186549B2 (en) * 2017-08-29 2021-11-30 Rutgers, The State University Of New Jersey Therapeutic indazoles
US11739326B2 (en) 2017-11-14 2023-08-29 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
WO2019124488A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬
US10696638B2 (en) * 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
EP3556362A1 (de) * 2018-04-16 2019-10-23 Ecole Polytechnique Federale De Lausanne (Epfl) Sting-inhibitoren
CA3102279A1 (en) 2018-06-01 2019-12-05 Cornell University Combination therapy for pi3k-associated disease or disorder
PT3837256T (pt) * 2018-08-17 2023-05-23 Novartis Ag Compostos e composições de ureia como inibidores de smarca2/brm-atpase
WO2020041065A1 (en) 2018-08-20 2020-02-27 Propagenix Inc. Epithelial cell spheroids
CA3110661A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
WO2020126968A2 (en) * 2018-12-20 2020-06-25 Bayer Aktiengesellschaft Urea derivatives
BR112022001054A2 (pt) * 2019-08-21 2022-03-15 Kalvista Pharmaceuticals Ltd Inibidores enzimáticos
JP2023522784A (ja) 2020-04-27 2023-05-31 ノバルティス アーゲー 眼細胞療法のための方法及び組成物
TW202237083A (zh) 2021-01-11 2022-10-01 美商英塞特公司 包含ｊａｋ路徑抑制劑及ｒｏｃｋ抑制劑之組合療法
CN115710255B (zh) * 2021-08-23 2025-05-06 上海交通大学 一类含有苯并杂环取代的脲类衍生物及其制备和用途
CN118159645A (zh) 2021-10-18 2024-06-07 埃维亚生命科学有限公司 组合物及使用其治疗肝纤维化的方法
EP4419120A2 (de) 2021-10-22 2024-08-28 Evia Life Sciences Inc. Verfahren zur herstellung von extrazellulären vesikeln sowie zusammensetzungen und verfahren zur verwendung davon
CN119504738A (zh) * 2023-08-25 2025-02-25 武汉人福创新药物研发中心有限公司 作为mrgprx2拮抗剂的化合物及其制备方法和应用
WO2025122714A1 (en) * 2023-12-06 2025-06-12 University Of Virginia Patent Foundation Haloperidol derivatives, pharmaceutical composition comprising said derivatives, and therapeutic use thereof
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito
CN120794957A (zh) * 2024-05-14 2025-10-17 中国药科大学 苯并含氮杂环类sting抑制剂及其医药用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
GB2009155B (en) 1977-11-07 1982-07-21 Leo Pharm Prod Ltd Chemical compounds
NL7902993A (nl) * 1978-04-24 1979-10-26 Rhone Poulenc Ind Nieuwe isochinolinederivaten, de bereiding ervan en farmaceutische preparaten, die de nieuwe isochinoline- derivaten bevatten.
US4694004A (en) 1984-07-09 1987-09-15 Fujisawa Pharmaceutical Co., Ltd. Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
GB8702288D0 (en) 1987-02-02 1987-03-11 Erba Farmitalia Cinnoline-carboxamides
CA1338012C (en) 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
WO1990005723A1 (fr) 1988-11-24 1990-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Composes de trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane et leur utilisation en medecine
ES2102367T3 (es) 1990-05-18 1997-08-01 Hoechst Ag Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
KR0133372B1 (ko) 1991-09-06 1998-04-23 고야 다다시 4-아미노(알킬)시클로헥산-1-카르복사미드 화합물 및 그 용도
US5508306A (en) 1992-11-13 1996-04-16 Synaptic Pharmaceutical Corporation Aromatic amine derivatives
DE4308014A1 (de) 1993-03-13 1994-09-15 Hoechst Schering Agrevo Gmbh Kondensierte Stickstoffheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
AU675484B2 (en) * 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
JP3775685B2 (ja) 1993-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド Ｐｄｅ▲ｉｖ▼およびｔｎｆ抑制剤としての化合物
DE4331179A1 (de) 1993-09-14 1995-03-16 Hoechst Schering Agrevo Gmbh Substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
CA2133620A1 (en) 1993-10-28 1995-04-29 Werner Hofheinz Aminoquinoline derivatives
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
EP1195372A1 (de) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-Heterozyklisch substitutierte Benzamid Deriviate mit antihypertensiver Wirkung
JPH10503501A (ja) 1994-08-03 1998-03-31 アスタ メディカ アクチエンゲゼルシャフト 抗喘息、抗アレルギー、抗炎症及び免疫修飾作用を有するインドール、インダゾール、ピリドピロール及びピリドピラゾール誘導体
DE19504367A1 (de) 1995-02-10 1996-08-14 Boehringer Mannheim Gmbh Neue Pyridin- bzw. Pyridazinderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH10147585A (ja) 1996-11-19 1998-06-02 Kyowa Hakko Kogyo Co Ltd 含酸素複素環化合物
AU2616595A (en) 1995-05-23 1996-12-11 Hoechst Schering Agrevo Gmbh Substituted 2,3-cycloalkenopyridines, process for preparing the same, agents containing the same and their use as pestic ides and fungicides
AU6526896A (en) 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
JP3193301B2 (ja) 1995-09-14 2001-07-30 麒麟麦酒株式会社 生理活性タンパク質ｐ１６０
SE9504062D0 (sv) * 1995-11-12 1995-11-12 Mytronic Ab Optical centering/coplanarity and electronic test device
JP3421217B2 (ja) 1995-11-20 2003-06-30 麒麟麦酒株式会社 Ｒｈｏ標的タンパク質Ｒｈｏキナーゼ
CZ292443B6 (cs) 1995-12-05 2003-09-17 Darwin Discovery Limited Benzofuransulfonamid, farmaceutický prostředek jej obsahující a jeho použití
CZ296163B6 (cs) 1996-05-20 2006-01-11 Karboxyamidy chinolinu jako inhibitory TNF a inhibitory PDE-IV
ATE239004T1 (de) 1996-05-20 2003-05-15 Darwin Discovery Ltd Benzofuran carboxamide und ihre therapeutische anwendung
JP4373497B2 (ja) 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
EP0907362A4 (de) 1996-06-27 1999-12-01 Smithkline Beecham Corp Il-8 rezeptor antagonisten
BR9711154A (pt) 1996-08-12 1999-08-17 Yoshitomi Pharmaceutical Agente farmac-utico contendo inibidor cinase rho
US5955496A (en) 1996-08-13 1999-09-21 The Regents Of The University Of California Dihydroxy-oxy-eicosadienoates
EA002113B1 (ru) 1996-09-04 2001-12-24 Пфайзер Инк. Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно)
EP0943613A4 (de) 1996-11-19 2002-07-10 Kyowa Hakko Kogyo Kk Sauerstoff enthaltende heterocyclische verbindungen
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
JPH11139969A (ja) 1997-08-07 1999-05-25 Tanabe Seiyaku Co Ltd 医薬組成物
DE69813605T2 (de) 1997-10-01 2004-02-12 Kyowa Hakko Kogyo Co., Ltd. Benzofuranderivate
EP1025087A1 (de) 1997-10-24 2000-08-09 Smithkline Beecham Plc Substituierte isochinolinderivate und ihre verwendung als anticonvulsiva
AU1983599A (en) 1998-01-26 1999-08-09 Kyowa Hakko Kogyo Co. Ltd. Oxygenic heterocyclic compounds
HUP0002353A3 (en) 1998-01-29 2001-11-28 Daiichi Asubio Pharma Co Ltd 1-cycloalkyl-1,8-naphthyridin-4-one derivatives with phoshodiesterase iv inhibitory activity and pharmaceutical compositions containing them
TW555759B (en) 1998-06-08 2003-10-01 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
GB9824160D0 (en) 1998-11-04 1998-12-30 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
GB9903919D0 (en) 1999-02-19 1999-04-14 Darwin Discovery Ltd Aminophenols and their therapeutic use
AU6917400A (en) 1999-08-31 2001-03-26 Alcon Laboratories, Inc. Use of 5-ht1b/1d agonists to treat otic pain

Also Published As

Publication number Publication date
US7217722B2 (en) 2007-05-15
EP1256574A4 (de) 2004-09-01
ES2377556T3 (es) 2012-03-28
WO2001056988A1 (en) 2001-08-09
EP1256574A1 (de) 2002-11-13
ES2377556T9 (es) 2013-07-09
AU2001230564A1 (en) 2001-08-14
EP1256574B1 (de) 2012-01-18
US20040102437A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
ATE541833T1 (de) Stickstoff-enthaltende verbindungen mit kinasehemmender wirkung sowie diese enthaltende medikamente
ATE206412T1 (de) Heterocyclische verbindungen als bradykinin antagonisten
DK0591528T3 (da) Pyrazolo[1,5-a]pyrimidinderivat og antiinflammatorisk middel, der indeholder dette
ATE480521T1 (de) Stickstoff enthaltende heterocyclische verbindungen
ATE496035T1 (de) Stickstoffenthaltende heterocyclische verbindungen
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
MXPA06001274A (es) Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio.
EP0978516A4 (de) 1-cycloalkyl-1,8-naphthyridin-4-on-derivate mit phosphodiesterase iv hemmender aktivität
ATE267814T1 (de) Substituierte kondensierte heterocyclische verbindungen
ATE203024T1 (de) Heterozyklische verbindungen, ihre herstellung und verwendung
DK1178967T3 (da) Quinolinderivater som inhibitorer af MEK-enzymer
ATE79380T1 (de) 2-substituierte-e-kondensierte(1,2,4>triazolo(1,5-c>pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
BR0315405A (pt) Compostos inibidores da integrase tricìclica pré-organizados
DK0625977T3 (da) Piperazinderivater som 5-1A-antagonister
ATE339409T1 (de) Trizyklische verbindungen
EP1364950A4 (de) Pyridopyrimidin- und naphthyridinderivate
DK0618193T3 (da) Nitrogenholdige, bicycliske derivater som prolyl-endopeptidaseinhibitorer
DE69427517D1 (de) Tetracyclische kondensierte heterocyclische Verbindungen zur Behandlung von seniler Demenz
ATE172193T1 (de) Piperazinderivate
ATE172454T1 (de) Pyridazinon derivate mit pharmazeutischer wirkung
ATE194982T1 (de) Benzoxazepin-derivate als cholinesterase- inhibitoren
EP1122253A4 (de) Quinalozinon-derivate
NO20053302D0 (no) Imidazolderivater med affinitet for alfa 2-reseptoraktivitet.
DK0613897T3 (da) Piperidinderivater med anti-histamin-og anti-leukotrienaktivitet
DE60239324D1 (de) Phenyl- und pyridyl-piperidine mit tnf-wirkung